

TYK2 Antibody (C-term)
Purified Rabbit Polyclonal Antibody (Pab)
Catalog # AP20922c**Specification**

TYK2 Antibody (C-term) - Product Information

Application	WB, IHC-P,E
Primary Accession	P29597
Other Accession	Q9R117
Reactivity	Human
Predicted	Mouse
Host	Rabbit
Clonality	Polyclonal
Isotype	Rabbit IgG

TYK2 Antibody (C-term) - Additional Information**Gene ID** 7297**Other Names**

Non-receptor tyrosine-protein kinase TYK2, TYK2

Target/Specificity

This TYK2 antibody is generated from a rabbit immunized with a KLH conjugated synthetic peptide between 887-922 amino acids from the C-terminal region of human TYK2.

Dilution

WB~~1:1000

IHC-P~~1:25

E~~Use at an assay dependent concentration.

Format

Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.

Storage

Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions

TYK2 Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.

TYK2 Antibody (C-term) - Protein Information**Name** TYK2**Function** Tyrosine kinase of the non-receptor type involved in numerous cytokines and interferons

signaling, which regulates cell growth, development, cell migration, innate and adaptive immunity (PubMed:[10542297](#), PubMed:[10995743](#), PubMed:[7657660](#), PubMed:[7813427](#), PubMed:[8232552](#)). Plays both structural and catalytic roles in numerous interleukins and interferons (IFN-alpha/beta) signaling (PubMed:[10542297](#)). Associates with heterodimeric cytokine receptor complexes and activates STAT family members including STAT1, STAT3, STAT4 or STAT6 (PubMed:[10542297](#), PubMed:[7638186](#)). The heterodimeric cytokine receptor complexes are composed of (1) a TYK2-associated receptor chain (IFNAR1, IL12RB1, IL10RB or IL13RA1), and (2) a second receptor chain associated either with JAK1 or JAK2 (PubMed:[10542297](#), PubMed:[25762719](#), PubMed:[7526154](#), PubMed:[7813427](#)). In response to cytokine-binding to receptors, phosphorylates and activates receptors (IFNAR1, IL12RB1, IL10RB or IL13RA1), creating docking sites for STAT members (PubMed:[7526154](#), PubMed:[7657660](#)). In turn, recruited STATs are phosphorylated by TYK2 (or JAK1/JAK2 on the second receptor chain), form homo- and heterodimers, translocate to the nucleus, and regulate cytokine/growth factor responsive genes (PubMed:[10542297](#), PubMed:[25762719](#), PubMed:[7657660](#)). Negatively regulates STAT3 activity by promoting phosphorylation at a specific tyrosine that differs from the site used for signaling (PubMed:[29162862](#)).

Tissue Location


Observed in all cell lines analyzed. Expressed in a variety of lymphoid and non-lymphoid cell lines

TYK2 Antibody (C-term) - Protocols

Provided below are standard protocols that you may find useful for product applications.


- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

TYK2 Antibody (C-term) - Images



Western blot analysis of lysate from HeLa cell line, using TYK2 Antibody (C-term) (Cat. #AP20922c). AP20922c was diluted at 1:1000. A goat anti-rabbit IgG H&L(HRP) at 1:10000

dilution was used as the secondary antibody. Lysate at 20ug.



Immunohistochemical analysis of paraffin-embedded human liver section using TYK2 Antibody (C-term) (Cat#AP20922c). AP20922c was diluted at 1:25 dilution. An undiluted biotinylated goat polyvalent antibody was used as the secondary, followed by DAB staining.

TYK2 Antibody (C-term) - Background

Probably involved in intracellular signal transduction by being involved in the initiation of type I IFN signaling. Phosphorylates the interferon-alpha/beta receptor alpha chain.

TYK2 Antibody (C-term) - References

- Firmbach-Kraft I.,et al.Oncogene 5:1329-1336(1990).
- Velazquez L.,et al.Cell 70:313-322(1992).
- Krolewski J.J.,et al.Oncogene 5:277-282(1990).
- Partanen J.,et al.Proc. Natl. Acad. Sci. U.S.A. 87:8913-8917(1990).
- Colamonici O.,et al.Mol. Cell. Biol. 14:8133-8142(1994).